November 20, 2023
Takeda Pharmaceutical said on November 17 that it has submitted a new drug application in Japan for its pUL97 kinase inhibitor maribavir for the treatment of cytomegalovirus (CMV) infections in organ transplants, including hematopoietic stem cell transplantations. The filing is...read more